Antibody drug bamlanivimab brought in world-wide revenue of $871.2 million, contributing much of the company’s 22% revenue growth in the fourth quarter of 2020.
source https://www.wsj.com/articles/eli-lilly-profit-rises-helped-by-covid-19-drug-sales-11611926977?mod=pls_whats_news_us_business_f
No comments:
Post a Comment